13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis

      research-article
      1 , 2 , 3 , 4 , * , 1 , 1 , 2 , 1 , 1 , 2 , 3 , 1 , 3 , 1 , 1 , 1 , 1 , 2 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 2 , 3 , 5 , 6 , 7 , 8 , 1 , 2 , 3 , 9 , 10 , 11 , 1 , 2 , 3 , 1 , 2 , 3 , *
      Frontiers in Pharmacology
      Frontiers Media S.A.
      pharmacogenetics, tardive dyskinesia, schizophrenia, perlecan/heparan sulfate proteoglycan 2 (HSPG2), meta-analysis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however, genetic factors play an important role. The Perlecan ( HSPG2) gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. To add to the evidence for this gene in TD, we conducted a meta-analysis specific to the relationship of HSPG2 rs2445142 with TD occurrence, while also adding our unpublished genotype data. Overall, we found a significant association of the G allele with TD occurrence ( p = 0.0001); however, much of the effect appeared to originate from the discovery dataset. Nonetheless, most study samples exhibit the same trend of association with TD for the G allele. Our findings encourage further genetic and molecular studies of HSPG2 in TD.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Perlecan is essential for cartilage and cephalic development.

          Perlecan, a large, multi-domain, heparan sulfate proteoglycan originally identified in basement membrane, interacts with extracellular matrix proteins, growth factors and receptors, and influences cellular signalling. Perlecan is present in a variety of basement membranes and in other extracellular matrix structures. We have disrupted the gene encoding perlecan (Hspg2) in mice. Approximately 40% of Hspg2-/- mice died at embryonic day (E) 10.5 with defective cephalic development. The remaining Hspg2-/- mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities. Only 6% of Hspg2-/- mice developed both exencephaly and chondrodysplasia. Hspg2-/- cartilage showed severe disorganization of the columnar structures of chondrocytes and defective endochondral ossification. Hspg2-/- cartilage matrix contained reduced and disorganized collagen fibrils and glycosaminoglycans, suggesting that perlecan has an important role in matrix structure. In Hspg2-/- cartilage, proliferation of chondrocytes was reduced and the prehypertrophic zone was diminished. The abnormal phenotypes of the Hspg2-/- skeleton are similar to those of thanatophoric dysplasia (TD) type I, which is caused by activating mutations in FGFR3 (refs 7, 8, 9), and to those of Fgfr3 gain-of-function mice. Our findings suggest that these molecules affect similar signalling pathways.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Research diagnoses for tardive dyskinesia.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction.

              The vertebrate neuromuscular junction (NMJ) remains the best-studied model for understanding the mechanisms involved in synaptogenesis, due to its relatively large size, its simplicity of patterning, and its unparalleled experimental accessibility. During neuromuscular development, each skeletal myofiber secretes and deposits around its extracellular surface an assemblage of extracellular matrix (ECM) proteins that ultimately form a basal lamina. This is also the case at the NMJ, where the motor nerve contributes additional factors. Before most of the current molecular components were known, it was clear that the synaptic ECM of adult skeletal muscles was unique in composition and contained factors sufficient to induce the differentiation of both pre- and postsynaptic membranes. Biochemical, genetic, and microscopy studies have confirmed that agrin, laminin (221, 421, and 521), collagen IV (α3-α6), collagen XIII, perlecan, and the ColQ-bound form of acetylcholinesterase are all synaptic ECM proteins with important roles in neuromuscular development. The roles of their many potential receptors and/or binding proteins have been more difficult to assess at the genetic level due to the complexity of membrane interactions with these large proteins, but roles for MuSK-LRP4 in agrin signaling and for integrins, dystroglycan, and voltage-gated calcium channels in laminin-dependent phenotypes have been identified. Synaptic ECM proteins and their receptors are involved in almost all aspects of synaptic development, including synaptic initiation, topography, ultrastructure, maturation, stability, and transmission. Copyright © 2011 Wiley Periodicals, Inc.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                18 September 2018
                2018
                : 9
                : 974
                Affiliations
                [1] 1Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , Toronto, ON, Canada
                [2] 2Department of Psychiatry, University of Toronto , Toronto, ON, Canada
                [3] 3Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON, Canada
                [4] 4Institute of Medical Science, University of Toronto , Toronto, ON, Canada
                [5] 5The Danek Gertner Institute of Human Genetics, Sheba Medical Center , Tel Hashomer, Israel
                [6] 6The Joseph Sagol Neuroscience Center, Sheba Medical Center , Tel Hashomer, Israel
                [7] 7Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel
                [8] 8Biological Psychiatry Laboratory and Hadassah BrainLabs, Hadassah-Hebrew University Medical Center , Jerusalem, Israel
                [9] 9Department of Psychiatry and Human Behavior, Long Beach Veterans Administration Health Care System, University of California , Irvine, Irvine, CA, United States
                [10] 10Columbia University, New York State Psychiatric Institute , New York City, NY, United States
                [11] 11Psychiatry and Behavioral Sciences, Pharmacology and Physiology, Chemistry of Life Processes Institute, Northwestern University Feinberg School of Medicine , Chicago, IL, United States
                Author notes

                Edited by: Bernardo Carpiniello, Università degli Studi di Cagliari, Italy

                Reviewed by: Alessio Squassina, Università degli Studi di Cagliari, Italy; Sulev Kõks, University of Tartu, Estonia

                *Correspondence: Clement C. Zai, clement.zai@ 123456camh.ca James L. Kennedy, jim.kennedy@ 123456camh.ca

                This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2018.00974
                6157325
                952b9094-2237-4599-8e0a-6f7fa6d39357
                Copyright © 2018 Zai, Lee, Tiwari, Lu, de Luca, Maes, Herbert, Shahmirian, Cheema, Zai, Atukuri, Sherman, Shaikh, Tampakeras, Freeman, King, Müller, Greenbaum, Lerer, Voineskos, Potkin, Lieberman, Meltzer, Remington and Kennedy.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 31 May 2018
                : 08 August 2018
                Page count
                Figures: 0, Tables: 3, Equations: 0, References: 51, Pages: 6, Words: 0
                Categories
                Pharmacology
                Original Research

                Pharmacology & Pharmaceutical medicine
                pharmacogenetics,tardive dyskinesia,schizophrenia,perlecan/heparan sulfate proteoglycan 2 (hspg2),meta-analysis

                Comments

                Comment on this article